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Edited by Veli-Pekka LehtoAbstract Overexpression of the epidermal growth factor recep-
tor (EGFR, ErbB1, HER1) is frequent in head and neck squa-
mous cell carcinomas (HNSCCs) and correlates with disease
progression. Inhibition of EGFR with the kinase inhibitor
AG1478 abolished receptor phosphorylation and reduced cell
proliferation. However, treatment of HNSCC cells with cetux-
imab (Erbitux), a monoclonal antibody designed to block the
EGFR ligand binding site, led to paradox EGFR activation
due to hyperphosphorylation of tyrosine 1173, however, with a
concomitant reduction in Erk1/2 phosphorylation levels. No pro-
nounced inﬂuence on cell proliferation levels could be observed
after treatment with this antibody. Since cetuximab appears able
to activate EGFR in HNSCC cell lines, it is necessary to rethink
the exact mechanisms by which cetuximab that recently was ap-
proved for the treatment of advanced head and neck cancer,
inhibits tumor growth.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Proliferation1. Introduction
Head and neck squamous cell carcinomas (HNSCCs) are the
sixth most-frequent cancer counting over 500000 new cases [1]
world-wide each year [2]. They are characterized by early, pre-
dominantly lymphatic metastatic spread [3]. The ﬁve year sur-
vival time of the patient drops dramatically if lymph node
metastases are present at the time of diagnosis. Overexpression
of the epidermal growth factor receptor (EGFR, ErbB1,
HER1), a receptor tyrosine kinase, is a hallmark of many epi-
thelial tumors [4,5] particularly of head and neck squamous
cell carcinomas [6,7] and is associated with tumor progression,
early metastatic spread and poor prognosis of HNSCC cancer
[7,8]. After ligand-stimulation and internalization of EGFR,
the receptor either recycles back to the plasma membrane, or
is directed to the lysosomal compartment for degradation [9].*Corresponding author. Fax: +49 6421 2862421.
E-mail address: mandic@med.uni-marburg.de (R. Mandic).
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doi:10.1016/j.febslet.2006.07.064Downregulation of EGFR due to internalization and subse-
quent lysosomal degradation is one mechanism that is targeted
by diverse anti-EGFR strategies. Ligand-binding results in
EGF receptor dimerization and autophosphorylation of its
cytoplasmic COOH-terminal domain. The major phosphoryla-
tion site is tyrosine 1173. Activated, i.e. phosphorylated,
EGFR can further activate diﬀerent signaling cascades such
as the MAPK (mitogen activated protein kinase)- or STAT
(signal transducer and activator of transcription)-pathways,
leading to transcription of EGFR-dependent genes [10].
Since EGFR has this high impact on tumor progression
and ﬁve-year survival of the patient several previous studies
focused on the development of inhibitors of EGFR function.
Small molecule inhibitors such as AG1478 or Geﬁtinib (Ires-
sa) target the intracellular kinase domain of the receptor by
competing with ATP, whereas monoclonal antibodies, such
as cetuximab (Erbitux) interact with the extracellular ligand
binding site to, supposedly, block ligand stimulation. Cetux-
imab was approved for the treatment of irinotecan-refractory
colorectal cancer [11] and recently also received approval for
the treatment of advanced head and neck cancer disease.
The aim of the present study was to evaluate the inﬂuence
EGFR inhibitors such as AG1478 and cetuximab have on
downstream signaling intermediates such as Erk1/2, cell cycle
progression and cisplatin sensitivity in HNSCC cell lines.2. Materials and methods
2.1. Cell lines and cell culture
The squamous cell carcinoma cell line UT-SCC-26A was as previ-
ously described by R. Gre´nman (University of Turku, Finland),
respectively [12]. The UMB-SCC-745 and UMB-SCC-864 (University
of Marburg) cell lines were derived from tumors of the oropharynx or
tongue, respectively (Table 1) [13]. Control keratinocytes were derived
from normal mucosa during a scheduled tonsillectomy after informed
consent of the patient. Cells were grown in DMEM media supple-
mented with 10% fetal calf serum (FCS) in the presence of penicillin
and streptomycin.
2.2. Treatment of cells with EGF and EGFR inhibitors
EGF and AG1478 (Tyrphostin) were purchased from Sigma (Taufkir-
chen, Germany) and Calbiochem (San Diego, CA), respectively. Cetux-
imab (Erbitux) was kindly provided by Merck (Merck Pharma
GmbH, Darmstadt, Germany). HNSCC cell lines were treated with 1,blished by Elsevier B.V. All rights reserved.
Table 1
HNSCC cell lines used in the study
HNSCC cell line Origin of primary Origin of specimen TNM Grading Age (years) Gender
UMB-SCC-745 Oropharynx Primary tumor site T4N2M0 G2 48 Male
UMB-SCC-864 Tongue Primary tumor site T2N2M0 G2 59 Male
UT-SCC-26A Hypopharynx Lymph node metastasis T1N2M0 G2 60 Male
4794 R. Mandic et al. / FEBS Letters 580 (2006) 4793–480010, 100 lg/ml cetuximab or 0.1, 1, 10, 100, 1000, 10000 ng/ml AG1478 for
13 h at 37 C, 5%CO2. For immunoﬂuorescence studies, cells were grown
on cover slides until 50% conﬂuent and stained as described below.
2.3. Antibodies
EGFR (1005), EGFR-FITC (R-1) and actin (C-2) primary anti-
bodies as well as all secondary FITC- or HRP-coupled antibodies were
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The anti-
(pTyr1173) EGFR antibody (9H2), directed against the major auto-
phosphorylation site of EGFR, was from Calbiochem. Antibodies
against Erk1/2 and phospho-Erk1/2 were from Upstate (Lake Placid,
NY) and Sigma, respectively.
2.4. SDS–PAGE and Western blot analysis
SDS–PAGE and Western blot analysis was performed under stan-
dard conditions using 35 lg of whole cell lysate protein per lane. In
short, nitrocellulose membranes were blocked with 3% milk/PBS and
incubated with the primary antibody (1:200–1:1000) over night at
4 C. Membranes were washed thrice for 10 min in 3% milk/PBS and
then were incubated with an HRP-coupled secondary antibody
(1:1000) for 1 h at room temperature. Membranes were washed and
bands were visualized on X-ray ﬁlm (Agfa, Cologne, Germany) using
the enhanced chemiluminescent (ECL) method (Amersham Biosci-
ences, Buckinghamshire, United Kingdom).Fig. 1. EGFR surface expression in three tested HNSCC cell lines. Depicted
UMB-SCC-864 (middle) and UT-SCC-26A HNSCC cell lines, showing exp
membrane staining in UMB-SCC-745 and UMB-SCC-864, whereas in UT-SC
arrows). A similar result is seen after FACS analysis (bottom), that was sho
compared to UT-SCC-26A (shift to the right).2.5. Immunocytochemistry
Cells were grown on cover slides in 6 well tissue culture plates
(Greiner Bio-One GmbH, Frickenhausen, Germany) until 50%
conﬂuent, ﬁxed with methanol (20 C) for 30 min and stained with
the EGFR-speciﬁc antibody (1:200) in the presence of 3%BSA/
0.3%NP40/PBS for 1 h. Subsequently, the cells were washed in
the same buﬀer (3%BSA/0.3%NP40/PBS) and incubated with a
secondary FITC-coupled antibody (1:250) for additional 45 min.
Fluorescent mounting medium was from DakoCytomation
GmbH (Hamburg, Germany). Negative controls (secondary anti-
body alone) did not show any signiﬁcant background staining. The
resulting FITC-signal was visualized by confocal laser scanning
microscopy (Ax70, Olympus Deutschland GmbH, Hamburg,
Germany).2.6. Measuring EGFR at the cell surface
The HNSCC cell lines UMB-SCC-745, UMB-SCC-864 and UT-
SCC-26A were grown as described above until 80% conﬂuent. Cells
were then rinsed with PBS, removed with a cell scraper (Greiner
Bio-One GmbH) and ﬁltered through a 50 lm ﬁlter membrane (Dako-
Cytomation GmbH) to remove cell clusters. Cells were then ﬁxed in
formalin (3.7% formaldehyde solution) for 20 min at 4 C and then
stained with an anti-EGFR-FITC antibody for 1 h. FACS analysis
was performed as described below.are confocal laser scanning micrographs of the UMB-SCC-745 (left),
ression and cellular localization of EGFR (green). Note the distinct
C-26A the membrane staining of the receptor is less pronounced (white
wing a higher EGFR surface ﬂuorescence in UMB-SCC-745 and -864
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Cells were treated for 48 h with 10 lg/ml AG1478 or 10 lg/ml cetux-
imab, respectively. Supernatants with detached and trypsinized cells
from the layer were ethanol-ﬁxed, digested for 1 h with 50 lg/ml
RNase (Sigma) and stained with propidium iodide (Sigma). FACS
analysis was performed with the BD FACSCalibur Flow Cytometer
(Becton Dickinson, Heidelberg, Germany) and calculated with the
ModFit LT software for Mac systems.
2.8. MTT viability assay
MTT viability assays were performed as previously described [13].
Cells were pretreated with 10 lg/ml AG1478 or 10 lg/ml cetuximab
for 13 h, respectively. Pretreated cells were exposed to cisplatin for
48 h. IC50 was calculated from the resulting dose–response curve. At
least three independent experiments were performed for each cell line.
The standard deviation (S.D.) varied between 0.05 and 0.2 depending
on the cell line and cisplatin concentration.UMB-SCC-745 UMB-SCC-86
MW
[kDa]
~170→
~170→
~44
~42
~44
~42
0 100.1 10010 100.1 100 1000010001
AG1478 [ng/mAG1478 [ng/ml]
UMB-SCC-864
0 101 1
Cetuximab [µg/m
UMB-SCC-745
MW
[kDa]
~170→
~170→
~44
~42
~44
~42
0 101 100
Cetuximab [µg/ml]
~42→
UMB-SCC-86UMB-SCC-745
MW
[kDa]
~170→
~170→
EGF [ng/ml]
0 10 100 100010.1
EGF [ng/ml]
0 10 10010.1
~42→
~42→
A
B
C
Fig. 2. (A) Variable induction of EGFR-phosphorylation in the three tested H
levels of EGF (0.1, 1, 10, 100 and 1000 ng/ml) all HNSCC cell lines react
Cetuximab treatment of HNSCC cell lines results in paradox hyperphosphor
rising cetuximab levels (1, 10 and 100 lg/ml) results in extensive hyperphosph
it also inhibits phosphorylation of the downstream molecules Erk1/2. (C) T
Incubation of the three HNSCC cell lines with rising levels (0.1, 1, 10, 100, 1
results in virtually complete inhibition of EGFR and Erk1/2 phosphorylatio3. Results
3.1. Cell surface localization of EGFR in HNSCC cell lines
To determine the level of cell surface EGFR, HNSCC cells
were stained for the receptor as described in Section 2 and
FACS analysis as well as confocal laser scanning microscopy
were used to evaluate EGFR localization (Fig. 1). Clear
membrane staining could be observed in UMB-SCC-745
and UMB-SCC-864, whereas in UT-SCC-26A the membrane
staining was less pronounced (Fig. 1, white arrows). FACS
analysis also pointed to lower EGFR surface levels in UT-
SCC-26A compared to the other two HNSCC cell lines
(Fig. 1, bottom).4 UT-SCC-26A
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reatment with AG1478 abolishes EGFR and Erk1/2 phosphorylation.
000 and 10 000 ng/ml) of the small-molecule kinase inhibitor AG1478
n at the highest concentration level (10000 ng/ml).
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sensitivity
Stimulation of UMB-SCC-745, UMB-SCC-864 and UT-
SCC-26A with rising concentrations of EGF resulted in a rise
of receptor phosphorylation, that was most pronounced in
UMB-SCC-864, already reaching a maximum at lowest EGF
levels (0.1 ng/ml), whereas in UMB-SCC-745 10–100 ng/ml
EGF were necessary to result in maximal receptor phosphory-
lation (Fig. 2A). In UT-SCC-26A a rise in receptor phosphor-
ylation is noted at 10 ng/ml EGF. This cell line generally
expressed lower levels of EGFR. At highest EGF levels (100
and 1000 ng/ml) total EGFR protein appeared reduced, pre-
sumably due to internalization-dependent degradation as pre-
viously described [9,14].
3.3. Treatment of HNSCC cell lines with cetuximab results in
paradox hyperphosphorylation of tyrosine 1173 in the
receptor
To test the inﬂuence of the inhibitor cetuximab on EGFR
activation levels, the HNSCC cell lines UMB-SCC-745,
UMB-SCC-864 and UT-SCC-26A were incubated with 1, 10
or 100 lg/ml of this antibody. Surprisingly, incubation with
cetuximab resulted in extensive EGFR-hyperphosphorylation
in all tested HNSCC cell lines (Fig. 2B). Interestingly, there
was also noted a reduction in phospho-Erk1/2 at high (10
and 100 lg/ml) cetuximab levels, which was particularly pro-0 100.1 10
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Fig. 3. (A) EGF-stimulation can overcome inhibition by AG1478. Stimulatio
with 10 lg/ml AG1478 overcomes the inhibition of this kinase inhibitor as
pronounced in the UMB-SCC-745 and UT-SCC-26A cell lines. (B) Cetuxim
phosphorylation but inhibits Erk1/2 phosphorylation. Treatment of the ce
concomitant incubation with saturating (1000 ng/ml) levels of EGF leads to
phosphorylation.nounced in the UMB-SCC-745 and UT-SCC-26A cell lines.
In the UMB-SCC-745 cell line there also was noted a reduction
in total Erk1/2 protein after incubation with cetuximab,
whereas in the other two cell lines there was no visible change
in total Erk1/2 expression levels (Fig. 2B).
3.4. AG1478 treatment abolishes EGF-receptor phosphorylation
Incubation of HNSCC cell lines with 10000 ng (10 lg)/ml
AG1478 resulted in complete inhibition of EGFR phosphory-
lation and a concomitant reduction of Erk1/2 phosphorylation
but did not aﬀect total EGFR or Erk1/2 expression levels
(Fig. 2C).
3.5. EGF treatment of HNSCC cell lines can overcome
inhibition by AG1478
Treatment of the HNSCC cell lines UMB-SCC-745, UMB-
SCC-864 and UT-SCC-26A with rising EGF levels during con-
comitant inhibition with 10 lg/ml AG1478 results in a reversal
of EGFR-inhibition after incubation with 1–100 ng/ml (UMB-
SCC-745) or 1–1000 ng/ml (UT-SCC-26A) EGF, respectively,
as documented by a rise in phosphorylated-EGFR and phos-
pho-Erk1/2 (Fig. 3A). UMB-SCC-864 appears more resistant
to reversal of inhibition compared with the latter 2 cell lines,
however, at 1000 ng/ml EGF some phosphorylated EGFR
can be detected here too (Fig. 3A). Note also the induction
of EGFR and Erk1/2 phosphorylation after stimulation with100 10001000
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ab-treatment during saturating levels of EGF further promotes EGFR
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further increase in EGFR phosphorylation but inhibition of Erk1/2
R. Mandic et al. / FEBS Letters 580 (2006) 4793–4800 4797EGF without AG1478 inhibition in all of tested cell lines
(Fig. 3A, compare left and right lanes).
3.6. Cetuximab-treatment of HNSCC cell lines during
saturating levels of EGF further induces phosphorylation of
EGFR but inhibits Erk1/2 phosphorylation
Incubation of UMB-SCC-745, UMB-SCC-864 and UT-
SCC-26A with rising levels of cetuximab (1, 10 and 100 lg/
ml) during concomitant stimulation with saturating levels
(1000 ng/ml) of EGF results in a further rise of EGFR phos-
phorylation, most pronounced in UT-SCC-26A and UMB-
SCC-745, whereas particularly at high cetuximab levels (10
and 100 lg/ml) phosphorylation of Erk1/2 was inhibited
(Fig. 3B). No clear change in total Erk1/2 expression levels
could be observed except for a slight reduction at 100 lg/ml
in UMB-SCC-745 (Fig. 3B). Reduction of total EGFR protein
after incubation with saturating EGF levels is similar as ob-
served in Fig. 2A and likely due to internalization-dependent
degradation of the protein [9,14].
3.7. Eﬀect of treatment with cetuximab or AG1478 on cell cycle
progression in HNSCC cell lines
To evaluate the inﬂuence treatment with the inhibitors
AG1478 or cetuximab has on tumor cell cycle, the HNSCC cell
lines UMB-SCC-745, UMB-SCC-864, UT-SCC-26A were
treated with 10 lg/ml AG1478 or 10 lg/ml cetuximab, stained
with propidium iodide and analysed by FACS (see Section 2).
No signiﬁcant change in the distribution of cell cycle check-
points was seen after treatment of cells with cetuximabFig. 4. Inﬂuence of cetuximab or AG1478 on the cell cycle. Cell cycle checkpo
UT-SCC-26A HNSCC cell lines with 10 lg/ml cetuximab or 10 lg/ml AG14
cells in G0/G1, S or G2/M phase. Also depicted is the relative amount of de(Fig. 4, middle panel), however, there was an elevation noted
in the amount of dead cells (sub G1-population) compared
to the control (Fig. 4, middle and upper panel). Treatment
of HNSCC cells with the kinase inhibitor AG1478 lead to a
reduction in proliferation, which was most pronounced in
the UT-SCC-26A cell line, where the S phase population
dropped from 12.4% to 2.5% (Fig. 4). Noteworthy, treatment
with AG1478 exhibited the highest numbers of dead cells
(sub G1-population) (Fig. 4).
3.8. Inﬂuence of EGFR inhibition on cell survival at diﬀerent
cisplatin concentrations
Pre-treatment of the three HNSCC cell lines with the
EGFR-speciﬁc inhibitor AG1478 resulted in major loss of via-
bility in all tested HNSCC cell lines (Fig. 5A, open squares).
Treatment with rising cisplatin levels could add only little to
further loss of cell viability (Fig. 5A). Pretreating the HNSCC
cell lines UMB-SCC-864 and UT-SCC-26A with cetuximab
(Fig. 5A, open circles) did not appear clearly diﬀerent from
the untreated cells (Fig. 5A, open diamonds) whereas in cetux-
imab-pretreated UMB-SCC-745 cells the cell viability ap-
peared reduced compared to untreated control cells (Fig. 5A).
3.9. Eﬀect of treatment with cetuximab or AG1478 on cell
proliferation and cisplatin IC50 in HNSCC cell lines
The level of cell proliferation and cisplatin IC50 was evalu-
ated for the same three HNSCC cell lines (UMB-SCC-745,
-864 and UT-SCC-26A). Cisplatin IC50 was calculated for
the kinase inhibitor AG1478 and the monoclonal, blockingint distribution after treatment of UMB-SCC-745, UMB-SCC-864 and
78 as described in Section 2. Shown is the relative percentage of viable
ad cells (sub G1-population).
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Fig. 5. Eﬀect of cetuximab or AG1478 treatment on cell viability and cisplatin sensitivity in HNSCC cell lines. (A) The HNSCC cell lines UMB-SCC-
745, -864 and -26A were pretreated with 10 lg/ml AG1478 (h) or 10 lg/ml cetuximab (s) and subsequently incubated with rising cisplatin
concentrations (see Section 2). The proportion [%] of living cells was determined with the MTT assay and plotted against the used cisplatin
concentration. Control cells not pretreated with inhibitor are shown as open diamonds (e). (B) Proliferation and cisplatin-ID50 values were
determined as described in Section 2. Shown is the mean of at least three independent experiments ± S.D.
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not show any clear eﬀects on proliferation or cisplatin IC50
in the UMB-SCC-745 or -864 cell lines (Fig. 5B, left and mid-
dle graphs), whereas cetuximab-treatment of UT-SCC-26A
could signiﬁcantly reduce cisplatin IC50 without aﬀecting cell
proliferation (Fig. 5B, right graph). The inhibitor AG1478 re-
duced cell proliferation in all three tested cell lines, however
with a variable eﬀect on cisplatin IC50 values (Fig. 5B).4. Discussion
The epidermal growth factor receptor (EGFR, ErbB1,
HER1) is overexpressed in a wide variety of epithelial tumors
such as breast, ovary, kidney, colorectal and non-small-cell
lung cancer (NSCLC) and frequently also in head and neck
squamous cell carcinomas (HNSCC) [14].
4.1. Ligand-stimulation and phosphorylation of EGFR
There are several ligands known that bind and activate
members of the ErbB tyrosine kinase receptor family. Ligands
which speciﬁcally activate EGFR are EGF, TGF-a and
amphiregulin. Since tyrosine 1173 is one of the most character-
ized and representative autophosphorylation sites in EGFR
this tyrosine was chosen to monitor for receptor-phosphoryl-
ation and activation.
After EGFR stimulation, the receptor is internalized from
the plasma membrane. Internalization and subsequent degra-dation of EGFR, e.g. after treatment with cetuximab report-
edly contributes to the overall inhibitory eﬀect of this
monoclonal antibody [15].
4.2. EGFR-kinase inhibitors
EGFR activation can be blocked by speciﬁc EGFR-kinase
inhibitors, such as geﬁtinib (ZD1839, Iressa), erlotinib
(Tarceva) or tyrphostin (AG1478) [11]. Erlotinib has shown
eﬃcacy as monotherapy or in combination with chemotherapy
in phase II trials and geﬁtinib appeared eﬀective as mono-
therapy or in combination with chemotherapy or chemoradio-
therapy [11]. Erlotinib and geﬁtinib were both approved by
the FDA (Food and Drug Administration) for the treatment
of relapsed non-small-cell lung cancer (NSCLC). However, de-
spite several promising trial reports, patient response rates
were often highly heterogenous [11]. Recently, two groups re-
ported that EGFR mutations are common in NSCLC and that
tumors with these mutations are more responsive to geﬁtinib
[16,17]. Subsequently, Mukohara et al. continued to demon-
strate on NSCLC-derived cell lines that NSCLC cell lines bear-
ing mutant EGFR were much more responsive to geﬁtinib
than such cell lines carrying the wt EGF-receptor and that
EGFR mutation status did not inﬂuence sensitivity to cetux-
imab [18]. In contrast to NSCLC, ﬁrst reports point to a low
incidence of EGFR kinase domain mutations in HNSCC can-
cer [19], however, more studies are necessary to clearly demon-
strate the impact EGFR mutations have in the development
and the treatment of HNSCC cancer.
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Ligand-mediated activation of the EGF receptor can be
inhibited by using monoclonal antibodies that block the extra-
cellular ligand binding domain. One of the most advanced
EGFR-speciﬁc blocking antibodies is cetuximab (Erbitux,
IMC-C225, ImClone Systems Inc., New York, NY, USA).
Cetuximab is a chimeric, humanized version of the original
mouse monoclonal mab225 antibody [20,21] in which the
mouse constant FC region was replaced by the human FC re-
gion to reduce immunogenicity in man. Cetuximab is directed
against the extracellular NH2-terminal domain of EGFR, spe-
ciﬁcally against the binding site of the receptor’s natural
ligands (EGF, TGF-a). As mentioned above, cetuximab also
induces EGF-receptor internalization and degradation, which
should contribute to the overall EGFR-inhibitory eﬀect of
the treatment [21]. In this study we also could observe
EGFR-internalization and degradation after treatment of
HNSCC cell lines with cetuximab similarly as observed after
EGF-treatment. However, it was quite surprising to observe
extensive EGFR-hyperphosphorylation in all tested HNSCC
cell lines after treatment with cetuximab. Expectedly, cetux-
imab should have resulted in reduction or even loss of
EGFR-phosphorylation since its purpose is to block ligand-
dependent activation (phosphorylation) of the receptor. On
the other hand, it appears not overly surprising that such an
antibody could induce this eﬀect since it intentionally was de-
signed to block the extracellular ligand binding site. This
potentially could have resulted in an antibody that under some
circumstances can mimic EGFR ligands (EGF, TGF-a). In-
deed, when looking at the recent literature of cetuximab, one
can ﬁnd examples of tumor cell lines particularly of NSCLC
cell lines that after treatment with cetuximab do not show
reduction but rather induction of receptor phosphorylation
[18,22]. Nevertheless, cetuximab has proven to be an eﬀective
antitumor agent. It recently was approved by the FDA for
the treatment of irinotecan-refractory, colorectal cancer [23]
and in a recent phase III trial cetuximab, when combined with
radiotherapy, showed eﬃcacy in advanced HNSCC cancer
[11]. To summarize, cetuximab was found to either block or
induce EGFR phosphorylation in tumor cell lines such as
observed in NSCLC-derived cell lines [18]. However, in this
study, that was carried out with HNSCC-derived cell lines,
cetuximab-treatment always resulted in, although between
individual HNSCC cell lines variable, paradox hyperphos-
phorylation of the receptor. Interestingly, despite extensive
hyperphosphorylation of EGFR by cetuximab, this antibody
still lead to inhibition of phosphorylation of the downstream
signaling molecules Erk1/2. Why a hyperphosphorylated
EGF-receptor is unable to further promote Erk1/2 activation
will be an interesting question to study. Potentially, this phos-
phorylated EGFR population is separated to a subcellular
compartment or is blocked by other molecules and thereby
cannot exert any further downstream signaling events.4.4. Inﬂuence of EGF, cetuximab or AG1478 treatment on
cisplatin sensitivity
One of the three tested HNSCC cell lines (UT-SCC-26A)
was particularly resistant to even highest (100 lM) levels of cis-
platin, whereas the other cell lines (UMB-SCC-745 and UMB-
SCC-864) lost viability at 25 lM cisplatin or higher. Less than
20% or 50% of cells remained viable at 100 lM cisplatin inUMB-SCC-745 or -864, respectively, whereas the viability of
UT-SCC-26A cells was even higher (app. 120%) relative to un-
treated cells (=100%). The EGFR-speciﬁc kinase inhibitor
AG1478 by itself could signiﬁcantly reduce cell viability. Addi-
tional cisplatin treatment could only add little to further reduc-
tion of cell viability. No clear eﬀects on cell viability could be
seen after treatment with cetuximab in UMB-SCC-864 and
UT-SCC-26A, whereas some reduction in cell viability could
be achieved in UMB-SCC-745 after treatment with this anti-
body.5. Conclusion
In this study we could demonstrate that in HNSCC cell lines
treatment with the monoclonal, antibody cetuximab (Erbi-
tux) leads to activation of the EGF receptor as documented
by phosphorylation of tyrosine 1173. However, cetuximab
was still able to inhibit phosphorylation of the downstream
signaling molecules Erk1/2. Further studies therefore need to
investigate the exact downstream events that are associated
with cetuximab-dependent EGFR activation in HNSCC cell
lines and how these mechanisms inﬂuence cell growth and cis-
platin sensitivity in head and neck cancer.
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